Pathogenesis of Atherosclerosis a Review

Total Page:16

File Type:pdf, Size:1020Kb

Pathogenesis of Atherosclerosis a Review 2016 Vol.2No.3:22 DOI 1O.)11 6l /2 41 1-)99X.1OOO}1 Pathogenesis of Atherosclerosis A Review Maria Aziz ln this review, we would discuss the chief pathways involved in the pathophysiology of atherosclerosis. We would also highlight the end terminal events of this sequel with due consideration to risk factors, clinical features, diagnosis and Director, Pri-Med Care, Lewisville, Texas treatment. The aim of the review is to get into the fine details of all possible 75067, U5A. causes and pathophysiologic mechanisms responsible for atherosclerosis so that new treatment modalities can emerge and reduce the morbidity and mortality [email protected] associated with atherosclerosis. l= ref.9723656942 August 05, 2016; August 22, 2OL6; August 29,2016 Aziz M, Yadav KS. Pathogenesis of Introduction Atherosclerosis. Med Clin Rev. 2016,2.3. Atherosclerosis has been derived from a Greek word, Athero meaning gruel [1]. Marchand introduced the term Discussion "atherosclerosis" describjng the assosciation of fatty degeneration and vessel stiffening [2]. lt's the patchy intramural thickening of We would discuss the chief pathways involved in the the subintima. The earliest lesion is the fatty streak. Fatty streak pathophysiology of atherosclerosis. We would also highlight the end events of this sequel with due consideration to risk evolve to fibrous plaque and unstable plaque are responsible for terminal clinical events. factors, clinical features, diagnosis and treatment. Atherosclerosis is marked by atheromas, patchy intimal Pathophysiology plaques. Most common location is lumen of medium sized and Atherosclerosis is a chronic inflammatory disease. Atherosclerosis plaque -namely large arteries. The has cellular component of begins with fatty streak which is a accumulation of lipid laden inflammatory cells, smooth muscle cells, a fibrous component of foam cells in the intimal layer of the artery [4]. Lipid retention -connective tissue and a fat component of lipids. Prominent risk is the first step in the pathogenesis of atherosclerosis which is factors of consideration are Hypertension, Diabetes, Dyslipidemia, followed by chronic inflammation at susceptible sites in the walls obesity, sedentary life style, Family history, smoking. Intraplaque of the major arteries lead to fatty streaks, which then progress to (Table 1) rupture, bleeding, thrombosis and stenosis cause symptoms. fibroatheromas which are fibrous in nature [5,6]. Diagnosis is clinical and definitive diagnosis is made through Atherosclerosis is a continuous progressive development. Fatty lmaging tests. Management plan includes behavior modifi€ations streak develop at 11-12 years and fibrous plaques at 15 30 years (Figure (Physical activity with low caloric diet, rich in fiber component) 1, depicts the conversion of Fatty Streak to Fibrous Plaques) [7] and they develop at the same anatomic sites as the and main class of drugs used in treatment are antiplatelet drugs fatty streaks making it more evident that fibrous plaques arise and antiatherogenic drugs. from fatty streak. Pathologic intimal thickening leads to fatty plaques, finally It is the leading cause of morbidity and mortality in the US and streak, leads to fibrous cap atheromas, lead to leading to sudden cardiac death western world. ln the current era cardiovascular disease (CVD) [8,9]. remains the MCC of death all over the world. In 2008, 17 million Fatty streaks evolve to atherosclerotic plaques which is composed deaths were recorded from CVD. More than 3 million of these of three components namely of inflammatory cells, smooth muscle a fibrous component of-connective tissue and a Fat deaths occurred in people below the age of 6o and could have cells, component of lipids [10]. largely been prevented [3]. There are growing inequalities in the occurrence and outcome of CVD between countries and social Endothelial Injury plays the inciting role. Turbulent blood flow classes. leads to endothelial dysfunction, it inhibits production of No, o Under License ofCreative Commons Attribution 3-O License I http//medical-clinical-reviews.imedpub.com/archive-php 2016 Vol.2 No. 3 :22 Table 1 Stages of Atherosclerosis: Modified AHA consensus classification based on morphologic descriptions. Nonatherosclero$c intimal lesions Normal accumulation of smooth muscle cells (SMCs) in the intima in the absence of lipid Intimalthickening Absent or macrophage foam cells. Superficial accumulation of foam cells without a necrotic core or fibrous cap; based on lntimalxanthoma animal and human data, such lesions usually regress. Progressive athercsclerotic lesions Pathologic intimal thickening sMC rich plaque with proteoglycan matrix and focal accumulation of extracellular lipid Absent Early necrosis: focal macrophage infiltration into areas of lipid pools with an overlying Fibrous cap atheroma fibrous cap Late necrosis: loss of matrix and extensive cellular debris with an overlying fibrous cap. A thin, fibrous cap (< 65 Bm) infiltrat€d by macrophages and lymphocytes with rare or Thin cap fibroatheroma absence oJ sMcs and a relativelv large underlying necrotic corej intraplaque hemorrhage/ Absent - fibrin mav be present. Lesions with acute thrombi Fibroatheroma with fibrous cap disruption; the luminalthrombus communicates with the occlusive or Plaque rupture underlying necrotic core nonocclu5rve Plaque composition, as abovej no communacation ofthe thrombus with the necrotic core; Plaque erosion Usually nonocclusive can occur on a plaque substrate of pathologic intimal thickening or fibroatheroma Eruptive (shedding) of calcified nodules with an underlying fibrocalcific plaque with calcifed nodule Usually nonocclusive minimal or absence of necrosis Lesions with healed thrombi Fibrotic (without calcifi cation) Collagen-rich plaque with 5ignificant luminal stenosis; lesions may contain large areas of calcification with few inflammatory cells and minimal or absence of necrosis; these Absent Fibrocalcific {+/- necrotic core) lesions may represent healed erosions or ruptures Lesion reference to AHA types V and Vl was discarded, because it failed to account for the 3 different fiorphologies {rupture, erosion, and calcified nodule)that give rise to acute coronary thrombosis- of clinically silent ruptures leads to multiple layer of healed tissue Fatty Streak Fibrous Plaque and the end result is sudden cardiac death. calcium deposits (15 yeaf) (11 - 12 year) - 30 as small aggregates convert later to large nodules in the wall. Erosion of endothelium leads to thrombosis. Increase plaque mass causes stenosis and finally leading to lethal ischemia [12]. Figure 1 Conversion of fatty streak to Fibrous plaques. There are two types of plaques stable and unstable I131. stable plaques regress or are static or they grow slowly. Unstables a potent vasodilator and stimulates production of adhesion plaques are complicated by erosion, fissure, rupture and cause molecules which attract inflammatorv cells, Other risk factors also stenosis. thrombosis, infarction. Most clinical events result from contribute to this step. The net result is Monocytes and T cells complications of unstable plaque, hence plaque stabilization can bind to the endothelial cells and migrate to the subendothelial reduce morbidity and mortality associated with atherosclerosis. space. Lipids in the blood, LDL, VLDL bind to endothelial cells and Plaque is ruptured by enzymes secreted by activated macrophages oxidize in the subendothelial space. Monocytes in subendothelial in the plaque. Once plaque ruptures, plaque contents get exposed space engulf oxidized LDL and transform to foam cells. Thls mark to circulating blood and the end result is thrombosis [14]. The the first stage i.e-, fatty streak. Macrophages further elaborate resultant thrombosis may change plaque shape, occlude lumen proinflammatory cytokines which recruit smooth muscle cells. of blood vessel, may embolise or the plaque contents may There is smooth muscle cell replication and increase in dense embolise. Low risk plaoues are more fibrous in content and 100% blockade while unstable extracellular matrix. End result lesion is a subendothelial fibrous have low lipids and do not cause plaques have thick lipid core and thin fibrous cap narrow lumen plaque composed of lipid core surrounded by smooth muscle <50% and tend to rupture unpredictably [15]. cells and connective tissue fibers (Figures 2 and 3) [11]. The end result of the stenosis caused by the plaques are There is sequential involvement of arterial layers, intima, then the Terminal Events-Acute Coronary Syndrome, Myocardial media and finally adventitia. Arterial wall lesions have a central Infarction, Fatal Arrhythmias, sudden cardiac death (Figures 4 cholesterol rich lipid core surrounded by inflammatory response. and 5 depict the terminal events that arise due to stenosis due Everv lesion has lipid accumulation and inflammation. Plaque to plaques) [16]. distorts media/adventitia, increases caliber of arterial lumen and decreases its size simultaneously. New Vasa Vasorum invade diseased intima, cause hemorrhage wilhin arterial wall, leading to Age, Family history, Male sex, smoking, Diabetes mellitus, intramural hemorrhage and increased fibrous tissue. Rupture of hypertension, alcohol, Chlamydia infection, Hyper thin fibrous caps leads to thrombosis and healing. cyclic healing homocysteinemia, Obesity, Sedentary lifestyle [17]. hft p://mediaal-clinical-reviews.imedpub.com/archive.php 2016. Vol.2 No.3:22 Lipid Retention Traditional Rlso Faciors Oxidation Modification /", // ^ |. t+ype{ension
Recommended publications
  • Clinical Appropriateness Guidelines Positron Emission Testing, Other PET Applications, Including Oncologic Tumor Imaging Effective Date: April 21, 2014
    Clinical Appropriateness Guidelines Positron Emission Testing, Other PET Applications, including Oncologic Tumor Imaging Effective Date: April 21, 2014 Proprietary and Confidential Date of Origin: 03/30/2005 Last reviewed: 11/14/2013 Last revised: 01/15/2013 Clinical Appropriateness Guidelines 8600 W Bryn Mawr Avenue South Tower - Suite 800 Chicago, IL 60631 P. 773.864.4600 Copyright © 2014. AIM Specialty Health. All Rights Reserved www.aimspecialtyhealth.com Table of Contents Administrative Guideline ..........................................................................................................3 Disclaimer ..............................................................................................................................................................3 Use of AIM’s Diagnostic Imaging Guidelines..........................................................................................................4 Multiple Simultaneous Imaging Requests ..............................................................................................................5 General Imaging Considerations ............................................................................................................................6 PET - Other PET Applications, Including Oncologic Tumor Imaging ......................................8 PET Bibliography ....................................................................................................................12 Table of Contents | Copyright © 2014. AIM Specialty Health. All Rights Reserved.
    [Show full text]
  • Impact of Preoperative Endoscopic Ultrasound in Surgical Oncology
    REVIEW Impact of preoperative endoscopic ultrasound in surgical oncology Endoscopic ultrasound (EUS) has a strong impact on the imaging and staging of solid tumors within or in close proximity of the upper GI tract. Technological developments during the last two decades have increased the image quality and allowed very detailed visualization of local tumor spread and lymph node affection. Current indications for EUS of the upper GI tract encompass the differentiation between benign and malignant lesions, the staging of esophageal, gastric and pancreatic cancer, and the procurement of a biopsy specimen through fine-needle aspiration. Various technical innovations during the past two decades have increased the diagnostic quality and have simultaneously strengthened the role of EUS in the clinical setting. This article will give a compressed summary on the current state of EUS and possible further technical developments. 1 KEYWORDS: 3D imaging elastosonography endoscopic ultrasound miniprobes Sascha S Chopra & oncologic surgery Michael Hünerbein† 1Department of General & Transplantation Surgery, Charité Campus Virchow-Clinic, Berlin, Conventional endoscopic ultrasound the so-called ‘miniprobes’ into the biliary system Germany Linear versus radial systems or the pancreatic duct in order to obtain high-res- †Author for correspondence: Department of Surgery & Surgical Endoscopic ultrasound (EUS) with flex- olution radial ultrasound images locally. Present Oncology, Helios Hospital Berlin, ible endoscopes is an important diagnostic and mini probes show a diameter of 2–3 mm and oper- 13122 Berlin, Germany Tel.: +49 309 417 1480 therapeutic tool, especially for the local staging ate with frequencies between 12 and 30 MHz. Fax: +49 309 417 1404 of gastrointestinal (GI) cancers, the differen- The main drawbacks of these devices are the lim- michael.huenerbein@ tiation between benign and malignant tumors, ited durability and the decreased depth of penetra- helios-kliniken.de and interventional procedures, such as biopsies tion (~2 cm).
    [Show full text]
  • Immunoscintigraphy and Radioimmunotherapy in Cuba: Experiences with Labeled Monoclonal Antibodies for Cancer Diagnosis and Treatment (1993–2013)
    Review Article Immunoscintigraphy and Radioimmunotherapy in Cuba: Experiences with Labeled Monoclonal Antibodies for Cancer Diagnosis and Treatment (1993–2013) Yamilé Peña MD PhD, Alejandro Perera PhD, Juan F. Batista MD ABSTRACT and therapeutic tools. The studies conducted demonstrated the good INTRODUCTION The availability of monoclonal antibodies in Cuba sensitivity and diagnostic precision of immunoscintigraphy for detect- has facilitated development and application of innovative techniques ing various types of tumors (head and neck, ovarian, colon, breast, (immunoscintigraphy and radioimmunotherapy) for cancer diagnosis lymphoma, brain). and treatment. Obtaining different radioimmune conjugates with radioactive isotopes OBJECTIVE Review immunoscintigraphy and radioimmunotherapy such as 99mTc and 188Re made it possible to administer radioimmuno- techniques and analyze their use in Cuba, based on the published lit- therapy to patients with several types of cancer (brain, lymphoma, erature. In this context, we describe the experience of Havana’s Clini- breast). The objective of 60% of the clinical trials was to determine cal Research Center with labeled monoclonal antibodies for cancer pharmacokinetics, internal dosimetry and adverse effects of mono- diagnosis and treatment during the period 1993–2013. clonal antibodies, as well as tumor response; there were few adverse effects, no damage to vital organs, and a positive tumor response in a EVIDENCE ACQUISITION Basic concepts concerning cancer and substantial percentage of patients. monoclonal antibodies were reviewed, as well as relevant inter- national and Cuban data. Forty-nine documents were reviewed, CONCLUSIONS Cuba has experience with production and radiola- among them 2 textbooks, 34 articles by Cuban authors and 13 by beling of monoclonal antibodies, which facilitates use of these agents.
    [Show full text]
  • Chapter 12 Monographs of 99Mtc Pharmaceuticals 12
    Chapter 12 Monographs of 99mTc Pharmaceuticals 12 12.1 99mTc-Pertechnetate I. Zolle and P.O. Bremer Chemical name Chemical structure Sodium pertechnetate Sodium pertechnetate 99mTc injection (fission) (Ph. Eur.) Technetium Tc 99m pertechnetate injection (USP) 99m ± Pertechnetate anion ( TcO4) 99mTc(VII)-Na-pertechnetate Physical characteristics Commercial products Ec=140.5 keV (IT) 99Mo/99mTc generator: T1/2 =6.02 h GE Healthcare Bristol-Myers Squibb Mallinckrodt/Tyco Preparation Sodium pertechnetate 99mTc is eluted from an approved 99Mo/99mTc generator with ster- ile, isotonic saline. Generator systems differ; therefore, elution should be performed ac- cording to the manual provided by the manufacturer. Aseptic conditions have to be maintained throughout the operation, keeping the elution needle sterile. The total eluted activity and volume are recorded at the time of elution. The resulting 99mTc ac- tivity concentration depends on the elution volume. Sodium pertechnetate 99mTc is a clear, colorless solution for intravenous injection. The pH value is 4.0±8.0 (Ph. Eur.). Description of Eluate 99mTc eluate is described in the European Pharmacopeia in two specific monographs de- pending on the method of preparation of the parent radionuclide 99Mo, which is generally isolated from fission products (Monograph 124) (Council of Europe 2005a), or produced by neutron activation of metallic 98Mo-oxide (Monograph 283) (Council of Europe 2005b). Sodium pertechnetate 99mTc injection solution satisfies the general requirements of parenteral preparations stated in the European Pharmacopeia (Council of Europe 2004). The specific activity of 99mTc-pertechnetate is not stated in the Pharmacopeia; however, it is recommended that the eluate is obtained from a generator that is eluted regularly, 174 12.1 99mTc-Pertechnetate every 24 h.
    [Show full text]
  • Clinical Applications of SPECT/CT: New Hybrid Nuclear Medicine Imaging System
    IAEA-TECDOC-1597 Clinical Applications of SPECT/CT: New Hybrid Nuclear Medicine Imaging System August 2008 IAEA-TECDOC-1597 Clinical Applications of SPECT/CT: New Hybrid Nuclear Medicine Imaging System August 2008 The originating Section of this publication in the IAEA was: Nuclear Medicine Section International Atomic Energy Agency Wagramer Strasse 5 P.O. Box 100 A-1400 Vienna, Austria CLINICAL APPLICATIONS OF SPECT/CT: NEW HYBRID NUCLEAR MEDICINE IMAGING SYSTEM IAEA, VIENNA, 2008 IAEA-TECDOC-1597 ISBN 978-92-0-107108-8 ISSN 1011–4289 © IAEA, 2008 Printed by the IAEA in Austria August 2008 FOREWORD Interest in multimodality imaging shows no sign of subsiding. New tracers are spreading out the spectrum of clinical applications and innovative technological solutions are preparing the way for yet more modality marriages: hybrid imaging. Single photon emission computed tomography (SPECT) has enabled the evaluation of disease processes based on functional and metabolic information of organs and cells. Integration of X ray computed tomography (CT) into SPECT has recently emerged as a brilliant diagnostic tool in medical imaging, where anatomical details may delineate functional and metabolic information. SPECT/CT has proven to be valuable in oncology. For example, in the case of a patient with metastatic thyroid cancer, neither SPECT nor CT alone could identify the site of malignancy. SPECT/CT, a hybrid image, precisely identified where the surgeon should operate. However SPECT/CT is not just advantageous in oncology. It may also be used as a one-stop- shop for various diseases. Clinical applications with SPECT/CT have started and expanded in developed countries.
    [Show full text]
  • Monoclonal Antibody Imaging) Using In-111 Satumomab Pendetide (Oncoscint) Or Tc-99M Arcitumomab (IMMU-4, CEA-Scan
    Medical Policy Radioimmunoscintigraphy Imaging (Monoclonal Antibody Imaging) Using In-111 Satumomab Pendetide (OncoScint) or Tc-99m Arcitumomab (IMMU-4, CEA-Scan) Table of Contents • Policy: Commercial • Coding Information • Information Pertaining to All Policies • Policy: Medicare • Description • References • Authorization Information • Policy History Policy Number: 638 BCBSA Reference Number: 6.01.36A NCD/LCD: N/A Related Policies None Policy Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members Radioimmunoscintigraphy using satumomab pendetide or arcitumomab as the monoclonal antibody may be MEDICALLY NECESSARY in patients with known or suspected recurrent colorectal carcinoma under the following conditions: • In patients with an elevated carcinoembryonic antigen level, who have no evidence of disease with other imaging modalities (i.e., CT), in whom a second-look laparotomy is under consideration, or • In patients with an isolated, potentially resectable recurrence identified with conventional imaging modalities (i.e., CT), for whom the detection of additional occult lesions would alter the surgical plan. Other applications of radioimmunoscintigraphy using In-111 satumomab pendetide (OncoScint) or Tc- 99m-arcitumomab (IMMU-4, CEA-Scan) are INVESTIGATIONAL, including, but not limited to: • Ovarian cancer • Breast cancer • Medullary thyroid cancer, and • Lung cancer. Prior Authorization Information Inpatient • For services described in this policy, precertification/preauthorization IS REQUIRED for all products if the procedure is performed inpatient. 1 Outpatient • For services described in this policy, see below for products where prior authorization might be required if the procedure is performed outpatient. Outpatient Commercial Managed Care (HMO and POS) Prior authorization is not required. Commercial PPO and Indemnity Prior authorization is not required.
    [Show full text]
  • Multicenter Study of Immunoscintigraphy with Radiolabeled Monoclonal Antibodies in Patients with Melanoma1
    [CANCER RESEARCH 46, 4817-4822, September 1986] Multicenter Study of Immunoscintigraphy with Radiolabeled Monoclonal Antibodies in Patients with Melanoma1 A. G. Siccardi,2 G. L. Buraggi, L. Callegaro, G. Mariani, P. G. Natali, A. Abbati, M. Bestagno, V. Caputo, L. Mansi, R. Masi, G. Panini-Ili, P. Riva, M. Salvatore, M. Sanguinati, L. Troncone, G. L. Turco, G. A. Scassettati, and S. Terrone Dipartimento di Biologia e Genetica, Università di Milano, Milano [A. G. S.J; Istituto Nazionale Tumori, Milano fG. L. B.J; Centro Ricerche-SORIN Biomedica, Saluggia [L. C..G.A. S.J; Istituto di Fisiologia Clínicadel Consiglio Nazionale delle Ricerche, Pisa [G. M.]; Istituto Tumori Regina Elena, Roma [P. G. N.]; Departments of Nuclear Medicine of Ospedale Maggiore, Bologna [A. A.], Spedali Civili, Brescia [M. B.], Università "La Sapienza", Roma [V. C.], Istituto Pascale, Napoli [L. M., M. Sai.], Ospedale di Careggi, Firenze fR. M.], Ospedale Bufalini-Cesena [G. P., P. R.J, Ospedali Galliera-Genova [M. San.], Università Cattolica, Roma [L. T.], Università di Torino, Torino [G. L. T.], Italy; and Department of Microbiology and Immunology, New York Medical College (S. F.], Valhalla, New York 10595 ABSTRACT in multiple metastatic lesions from different anatomic sites (9); A multicenter study was performed to analyze the efficacy of "Tc- (c) it is undetectable in normal tissues except in hair bulbs and and '"In-labeled F(ab')2 fragments of monoclonal antibody (MoAb) in limited areas of the Malpighian layer (7, 10); (d) it is present only in minute amounts in serum even in patients with advanced 225.28S (reactive with a high molecular weight melanoma associated antigen) to radioimage malignant lesions in patients with melanoma.
    [Show full text]
  • Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma
    Current Urology Reports (2019) 20:56 https://doi.org/10.1007/s11934-019-0932-2 NEW IMAGING TECHNIQUES (S RAIS-BAHRAMI AND K PORTER, SECTION EDITORS) Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma Vidhya Karivedu1 & Amit L. Jain2 & Thomas J. Eluvathingal3 & Abhinav Sidana4,5 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review The clinical role of fluorine-18 fluoro-2-deoxyglucose (FDG)-positron emission tomography (PET) in renal cell carcinoma (RCC) is still evolving. Use of FDG PET in RCC is currently not a standard investigation in the diagnosis and staging of RCC due to its renal excretion. This review focuses on the clinical role and current status of FDG PET and PET/CT in RCC. Recent Findings Studies investigating the role of FDG PET in localized RCC were largely disappointing. Several studies have demonstrated that the use of hybrid imaging PET/CT is feasible in evaluating the extra-renal disease. A current review of the literature determines PET/CT to be a valuable tool both in treatment decision-making and monitoring and in predicting the survival in recurrent and metastatic RCC. Summary PET/CT might be a viable option in the evaluation of RCC, especially recurrent and metastatic disease. PET/CT has also shown to play a role in predicting survival and monitoring therapy response. Keywords Fluorodeoxyglucose (FDG) . Positron emission tomography/computed tomography (PET/CT) . Metabolically active renal cell carcinoma . Restaging . Metastases . Therapy monitoring Introduction common type, is potentially more metastatic than the other two variants [3]. RCC, in its early stages, has non-specific Renal cell carcinoma (RCC) ranks as the seventh leading disease-related symptoms, making early diagnosis a chal- cause of cancer-related deaths in the USA and accounts to lenge.
    [Show full text]
  • The Level of C.Pneumoniae, Cytomegalovirus, and H.Pylori Antibody in a Patient with Coronary Heart Disease
    Vol 11, No 4, October – December 2002 Microorganism antibodies in CHD patient 211 The level of C.pneumoniae, Cytomegalovirus, and H.pylori antibody in a patient with coronary heart disease Dasnan Ismail Abstrak Aterosklerosis sampai saat ini merupakan penyebab utama morbiditas dan mortalitas di negara maju. Meskipun modifikasi faktor risiko di negara maju telah dapat menurunkan kekerapan aterosklerosis namun penurunan ini mulai menunjukkan grafik yang mendatar. Keadaan ini merangsang para peneliti untuk mencari faktor pajanan lingkungan termasuk faktor infeksi yang dapat mempengaruhi proses aterosklerosis. Telah dilakukan penelitian potong lintang dari bulan Maret 1998 sampai Agustus 1998 terhadap 122 orang pasien yang secara klinis menunjukkan penyakit jantung koroner yang menjalani kateterisasi jantung, terdiri dari 92 orang laki-laki dan 30 orang perempuan dengan rerata umur 55 tahun. Pasien diperiksa secara klinis dan laboratorium (gula darah, kolesterol, trigliserida dan antibodi terhadap C.pneumoniae, Cytomegalovirus dan H.pylori). Pada penelitian ini didapatkan perbedaan kadar kolesterol, trigliserida dan HDL antara kelompok stenosis koroner dan non stenosis. Sedangkan kadar antibodi C.pneumoniae, Cytomegalovirus, H.pylori tidak berbeda bermakna. Penelitian ini belum dapat menyimpulkan pengaruh antibodi terhadap aterosklerosis karena pada kelompok non stenosis tidak dapat disingkirkan kemungkinan terjadinya aterosklerosis mengingat rerata umur subyek penelitian 55 tahun. Penelitian mengenai interaksi infeksi dengan risiko tradisional serta gender dan nutrisi diperlukan untuk mendapat jawaban yang lebih jelas tentang pengaruh infeksi terhadap aterosklerosis. (Med J Indones 2002; 11: 211-4) Abstract Atherosclerosis is still the chief cause of morbidity and mortality in developed nations. Even though in developed nations the modification of risk factors is able to reduce the prevalence rate of atherosclerosis, such reduction is starting to slow down.
    [Show full text]
  • 18F-FDG PET and PET/CT in Fever of Unknown Origin*
    CONTINUING EDUCATION 18F-FDG PET and PET/CT in Fever of Unknown Origin* Johannes Meller1, Carsten-Oliver Sahlmann1, and Alexander Konrad Scheel2 1Department of Nuclear Medicine, University of Go¨ttingen, Go¨ttingen, Germany; and 2Department of Nephrology and Rheumatology, University of Go¨ttingen, Go¨ttingen, Germany 18F-FDG PET seems to be more sensitive. It is expected that Fever of unknown origin (FUO) was originally defined as recurrent PET/CT technology will further improve the diagnostic impact fever of 38.3°C or higher, lasting 223 wk or longer, and undiag- of 18F-FDG PET in the context of FUO, as already shown in the nosed after 1 wk of hospital evaluation. The last criterion has un- oncologic context, mainly by improving the specificity of the dergone modification and is now generally interpreted as no method. diagnosis after appropriate inpatient or outpatient evaluation. Key Words: FDG; PET/CT; fever of unknown origin; FUO; infec- The 3 major categories that account for most FUOs are infec- tion; inflammation tions, malignancies, and noninfectious inflammatory diseases. J Nucl Med 2007; 48:35–45 The diagnostic approach in FUO includes repeated physical investigations and thorough history-taking combined with standardized laboratory tests and simple imaging procedures. Nevertheless, there is a need for more complex or invasive tech- niques if this strategy fails. This review describes the impact of Fever of unknown origin (FUO) was defined in 1961 18F-FDG PET in the diagnostic work-up of FUO. 18F-FDG accu- by Petersdorf and Beeson as recurrent fever of 38.3°Cor mulates in malignant tissues but also at the sites of infection higher, lasting 223 wk or longer, and undiagnosed after and inflammation and in autoimmune and granulomatous dis- 1 eases by the overexpression of distinct facultative glucose trans- 1 wk of hospital evaluation ( ).
    [Show full text]
  • Pathophysiology of Peripheral Arterial Disease and Risk Factors for Its Development
    JOHN R. BARTHOLOMEW, MD* JEFFREY W. OLIN, DO* Section Head, Vascular Medicine Professor of Medicine and Director of Vascular Medicine Department of Cardiovascular Medicine Zena and Michael A. Wiener Cardiovascular Institute Cleveland Clinic Mt. Sinai School of Medicine Cleveland, OH New York, NY Pathophysiology of peripheral arterial disease and risk factors for its development ■ ABSTRACT ■ PATHOPHYSIOLOGY OF PAD Peripheral arterial disease (PAD) is a systemic Atherosclerosis is a complex process that involves atherosclerotic process for which the major risk endothelial dysfunction, lipid disturbances, platelet factors are similar to those for atherosclerosis in activation, thrombosis, oxidative stress, vascular the carotid, coronary, and other vascular beds. smooth muscle activation, altered matrix metabolism, Among the traditional risk factors for PAD, those remodeling, and genetic factors.2 More recently, the with the strongest associations are advanced age, role of inflammation in all stages of atherosclerosis 3 smoking, and diabetes mellitus. More recently, a development has been widely recognized. number of nontraditional risk factors for PAD have Atherosclerosis frequently develops at arterial bifur- cations and branches where endogenous atheroprotec- also been recognized. This article briefly reviews tive mechanisms are impaired as a result of the effects the pathophysiology of PAD and the evidence sup- of disturbed flow on endothelial cells.2 Risk factors such porting established and emerging risk factors for as increased age, diabetes mellitus, smoking, eleva- its development. tions in total and low-density lipoprotein (LDL) cho- lesterol, and hypertension play important roles in both eripheral arterial disease (PAD) refers to the initiation and the acceleration of this process.2 atherosclerotic and thromboembolic process- es that affect the aorta, its visceral arterial The stages of atherosclerosis branches, and arteries of the lower extremi- Pathologically, the stages of atherosclerosis are divided P1 ties.
    [Show full text]
  • The Pathobiology of the Saccular Cerebral Artery Aneurysm Rupture
    To those of us carrying saccular cerebral artery aneurysms, - and to my family Th e Neurosurgery Research Group, Biomedicum Helsinki Department of Neurosurgery, University of Helsinki Department of Neurosurgery, University of Kuopio Transplantation Laboratory, University of Helsinki The Pathobiology of Saccular Cerebral Artery Aneurysm Rupture and Repair -a Clinicopathological and Experimental Approach Juhana Frösen ACADEMIC DISSERTATION To be publicly discussed by the permission of the Medical Faculty of the University of Helsinki in the lecture hall of Töölö Hospital on the 15th of September 2006 at 12 o’clock noon. Helsinki 2006 Supervised by Professor Juha Jääskeläinen Department of Neurosurgery Kuopio University Hospital and Marjukka Myllärniemi, MD PhD University of Helsinki Reviewed by Docent Timo Kumpulainen Department of Neurosurgery Oulu University Central Hospital and Docent Anne Räisänen-Sokolowski Department of Pathology University of Helsinki Discussed with Associate Professor Robert M Friedlander Department of Neurosurgery Harvard Medical School ISBN 952-92-0787-5 (paperback) ISBN 952-10-3330-4 (PDF) Abbreviations 15-LOX 15-lipoxygenase enzyme AAA Abdominal aortic aneurysm ACA Anterior cerebral artery AcomA Anterior communicating artery AICA Anterior inferior cerebellar artery APKD Autosomal polycystic kidney disease ApoB Apolipoprotein B ApoE Apolipoprotein E BA Basilar artery bFGF-R Receptor for basic fi broblast growth factor EEL External elastic lamina ELISA Enzyme immunoabsorbent assay eNOS Endothelial nitric oxide
    [Show full text]